- Cardiovascular diseases
- Metabolic diseases
- Autoimmune disorders
Types and Sizes
- Phase II and phase III
- Large and Small Trials
- Double blinded
- Open label
Trials that the biostatisticians at Frontier’s ISC have collaborated on have been published in numerous scientific papers in high-ranked scientific journals, including the ones below.
Fisher M, Roecker EB, DeMets D: The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Information Journal 35(1):115-29, 2001.
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ,Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, and DeMets DL for thePROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. New Engl J Med 325:1468-1475, 1991.
Packer M, O’Connor CM, Ghali JK, Carson, PE, Belkin RN, Miller, AB, Neuberg GW, FridD, Wertheimer JH, Cropp AB, DeMets DL for the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) Study Group. Effect of amlodipine on morbidity in severe chronic heart failure. New Engl J Med 335(15):1107-1114, 1996.
MERIT-HF Study Group (includes DeMets DL): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trials in congestive heart failure (MERIT-HF). Lancet 353: 2001-2007, 1999.
Frontier Science group, which I worked for many years on a large lipid drug program, are very impressive. They have perfect technical and operational insights in supporting IDMCs and maintain adequate collaborations with sponsors. Thanks for the Frontier Science group!!
As Chair of numerous Data Monitoring Committees during the past two decades I can safely attest that an Independent Statistical Center is a crucial and indispensable component. Frontier Science is among the very few in the entire United States who receive my wholehearted endorsement.